Logo.png
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
17. Oktober 2023 08:01 ET | Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
Logo.png
Chronic Hepatitis B Market to Observe Stunning Growth at a CAGR of 13.4% by 2032 | DelveInsight
16. Mai 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, May 16, 2023 (GLOBE NEWSWIRE) -- Chronic Hepatitis B Market to Observe Stunning Growth at a CAGR of 13.4% by 2032 | DelveInsight The chronic hepatitis B market is expected to grow...
AMR Logo.png
Global Chronic Hepatitis B (CHB) Market to Reach USD 6.1 Billion by 2031: Says AMR
01. November 2022 03:38 ET | Allied Market Research
Portland, OR, Nov. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Chronic Hepatitis B (CHB) Market size was estimated at $4.6 billion in 2021...
Arbutus Biopharma Logo
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
08. Juni 2022 02:05 ET | Arbutus Biopharma Corporation
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Logo.png
Chronic Hepatitis B Pipeline Analysis: Emerging Therapies, Key Companies, and Treatment Outlook | DelveInsight
11. Mai 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, May 11, 2022 (GLOBE NEWSWIRE) -- Chronic Hepatitis B Pipeline Analysis: Emerging Therapies, Key Companies, and Treatment Outlook | DelveInsight Chronic Hepatitis B Pipeline...